Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or Both
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or Both
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.
Inclusion Criteria:
Exclusion Criteria:
San Miguel de Tucuimán, Tucumán Province 4000, Argentina
City of Buenos Aires, C1056ABH, Argentina
City of Buenos Aires, C1056ABI, Argentina
Porto Alegre, Rio Grande do Sul 90430-001, Brazil
Essen, 45147, Germany
Münster, 48153, Germany
Goudi/Athens, 11527, Greece
Budapest, Pest County 1036, Hungary
Budapest, Pest County 1134, Hungary
New Delhi, National Capital Territory of Delhi 110029, India
Puducherry, Tamil Nadu 605006, India
Herzeliya, Israel 4630945, Israel
Sosnowiec, 41-209, Poland
Bucharest, Bucharest 020475, Romania
Kaoshiung, 807, Taiwan